North America TB Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing (NAT), Skin Test / Mantoux Test (TST), Blood Test / Serology Test, SMEAR Microscopy, Cultured-Based Tests, Radiography Tests, Others), By End-User (Hospitals and Diagnostic Laboratories, Physician’s Office Laboratories, Reference Laboratories, Academics and Research Facilities) and By Country (US, Canada) Forecasts, 2026-2034

Last Updated: September 25, 2026 | Author: Debashree Bora | Format:

North America TB Diagnostics Market Size

The North America TB diagnostics market size was valued at USD 540.00 million in 2025 and is projected to reach USD 569.59 million in 2026 and USD 872.82 million by 2034, growing at a CAGR of 5.48% during the forecast period 2026-2034.

Tuberculosis (TB) is an infectious illness caused by Mycobacterium tuberculosis bacteria (MTB). Tuberculosis is most associated with the lungs, although it may also affect other regions of the body. Most infections are asymptomatic, which is known as latent TB. Roughly 10% of latent infections proceed to active illness, which kills about half of individuals afflicted if left untreated. A persistent cough with bloody sputum, fever, night sweats, and weight loss are all hallmark indications of active tuberculosis. Weight loss gave rise to the historical phrase "consumption." Other organ infections can generate a variety of symptoms.

The bacterium Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.

One of the primary drivers driving market growth is the high prevalence of TB in the region, as well as favourable health-care policies. According to the World Economic Forum, North America has a robust economy, accounting for 27.95% of global GDP, which is one of the elements influencing the healthcare sector. When comparing the two countries, the US spends more on healthcare than Canada. Additionally, the industry is being driven by greater rise in expenditure for private hospital care, physician, health insurance, and clinical services. Furthermore, the need for TB diagnosis tools and medicines is reflected in healthcare and public spending, which serves as a key driver for this market. Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread.

North America TB Diagnostics Market Size

Download a Free Sample To learn more about this report.

Multiplex Molecular TB Assays

The North America TB Diagnostics Market analysis shows that multiplex molecular TB assays are gaining relevance as diagnostic programs seek to detect TB and multiple drug-resistance markers from the same clinical sample. The transition toward broader molecular panels allows laboratories to obtain more diagnostic information in a single test, while WHO’s 2025 diagnostic guidance includes automated NAAT technologies that support simultaneous TB detection and resistance testing. This shift supports faster diagnostic decisions and more efficient molecular testing workflows across North America.

Genomic Detection of Emerging Drug Resistance

Genomic detection of drug resistance is becoming more important as laboratories need to identify resistance mutations before conventional culture-based testing is complete. The transition toward targeted next-generation sequencing allows detection of resistance-associated mutations across multiple drugs, with the CDC’s MDDR tNGS assay examining 24 amplicons across 16 genes and providing information on more than 12 antituberculosis drugs. This approach supports earlier treatment selection and strengthens genomic surveillance of drug-resistant TB in North America.

North America TB Diagnostics Market Segmentation Analysis

By Test Type

Nucleic Acid Testing (NAT) is a key diagnostic approach because it rapidly detects Mycobacterium tuberculosis and can also support early identification of drug resistance.The Skin Test / Mantoux Test remains widely used for identifying TB infection, particularly in screening and targeted testing programs. Blood-based TB testing supports infection screening by measuring the immune response to TB-related antigens.Smear microscopy provides a relatively quick method for examining respiratory specimens and identifying acid-fast bacilli during TB evaluation.Culture-based testing remains an important laboratory method because it provides confirmation of TB disease and supports drug susceptibility testing.Radiography tests support TB diagnosis by identifying abnormalities in the lungs that may indicate active pulmonary disease. Other diagnostic methods complement established testing approaches in cases requiring additional clinical or laboratory evaluation.

North America TB Diagnostics Market Size By Segments

Request Customizationto receive a tailored report.

By End-User

Hospitals and diagnostic laboratories represent important end users because they provide comprehensive TB testing and manage patients requiring diagnostic confirmation and treatment decisions. Physician’s office laboratories support initial TB screening and diagnostic evaluation by providing testing closer to routine patient care settings. Reference laboratories handle specialized and complex TB testing, including molecular and confirmatory laboratory procedures that may not be available in smaller facilities.Academic and research facilities support the development and evaluation of new TB diagnostic technologies, testing methods, and drug-resistance detection approaches.

North America TB Diagnostics Market Share By Segments

Speak to an Analystto discuss market opportunities.

North America TB Diagnostics Market Regional Outlook

The North America TB Diagnostics Market accounted for the largest regional share of 36.4% in 2025. The region benefits from advanced healthcare infrastructure, established diagnostic laboratories, and continued demand for accurate tuberculosis detection. Increased adoption of rapid molecular testing and drug-resistance diagnostics further supports market growth.

The CDC has set a 2030 target of reducing TB incidence in the U.S. to 1.48 cases per 100,000 population, alongside targets for improved case management and laboratory reporting, supporting continued demand for TB diagnostic testing.The Government of Canada aims to eliminate TB among Inuit across Inuit Nunangat by 2030 and reach a pre-elimination incidence of less than 10 notified cases per million population across Canada by 2035, requiring continued screening, detection, and diagnostic efforts.

North America TB Diagnostics Market Competitive Landscape

The North America TB Diagnostics Market is moderately fragmented, with the market ecosystem comprising global diagnostic manufacturers, molecular testing companies, laboratory equipment providers, specialized tuberculosis diagnostic firms, clinical laboratories, public health laboratories, biotechnology companies, and regional diagnostic suppliers.

Established players compete mainly through diagnostic accuracy, sensitivity and specificity, regulatory approvals, clinical validation, product reliability, testing speed, broad diagnostic portfolios, laboratory integration, and distribution networks, while the market ecosystem includes emerging players that compete through rapid molecular testing, drug-resistance detection, multiplex assays, portable solutions, automation, cost efficiency, and innovative specimen-based testing technologies.

List of Key and Emerging Players in North America TB Diagnostics Market

Danaher Corporation

Thermo Fisher Scientific

Abbott Laboratories

Hologic, Inc.

Oxford Immunotec

Key Industry Developments

May 2026

QIAGEN announced plans to launch a fully automated Sample-to-Insight workflow for QuantiFERON latent tuberculosis testing through a new partnership with Inpeco. The company also unveiled plans for an AI-enabled TB risk stratification tool and continued expansion of the LIAISON QuantiFERON-TB Gold Plus II workflow in the U.S., enhancing automation and laboratory efficiency for TB diagnostics.

April 2026

Cepheid expanded its strategic collaboration with Oxford Nanopore Technologies to advance integrated molecular diagnostic workflows for infectious disease testing. The partnership aims to accelerate development of rapid genomic testing solutions that support future infectious disease and tuberculosis diagnostic capabilities.

February 2026

QIAGEN's LIAISON QuantiFERON-TB Gold Plus II assay was launched in the United States following U.S. availability, expanding high-throughput latent tuberculosis testing capabilities through the DiaSorin LIAISON platform.

January 2026

The U.S. FDA approved a manufacturing process update for QIAGEN's QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus tests, supporting continued production and supply of one of the leading interferon-gamma release assays (IGRAs) used for tuberculosis diagnosis in North America.

Report Scope

Segmentation

By Test Type 7

Nucleic Acid Testing (NAT)
Skin Test / Mantoux Test (TST)
Blood Test / Serology Test
SMEAR Microscopy
Cultured-Based Tests
Radiography Tests
Others

By End-User 4

Hospitals and Diagnostic Laboratories
Physician’s Office Laboratories
Reference Laboratories
Academics and Research Facilities

Competitive Coverage Danaher Corporation · Thermo Fisher Scientific · Abbott Laboratories · Hologic, Inc. · Oxford Immunotec

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The North America TB diagnostics market was valued at USD 569.59 million in 2026.

The global Market of North America TB Diagnostics growing at a CAGR of 5.48%.

The quick molecular diagnostics segment is expected to dominate over the forecast period.

Danaher Corporation, Thermo Fisher Scientific, Abbott Laboratories, Hologic, Inc., Oxford Immunotec., are the prominent players in the North America TB Diagnostics Market.

The growing geriatric population base are some key drivers supporting the growth of the North America TB Diagnostics Market.

About the Author

Debashree Bora

Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.